Exelon Patch rivastigmine regulatory update

Novartis disclosed in its 2Q11 earnings that Japan's Ministry of Health, Labor and Welfare (MHLW) approved Exelon Patch rivastigmine to treat mild to moderate Alzheimer's disease. The pharma also disc...